Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Change in Cash: 2011-2025

Historic Change in Cash for Abeona Therapeutics (ABEO) over the last 14 years, with Sep 2025 value amounting to -$80.7 million.

  • Abeona Therapeutics' Change in Cash fell 331.29% to -$80.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.2 million, marking a year-over-year increase of 509.75%. This contributed to the annual value of $8.9 million for FY2024, which is 3370.31% up from last year.
  • According to the latest figures from Q3 2025, Abeona Therapeutics' Change in Cash is -$80.7 million, which was down 154.64% from $147.6 million recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' Change in Cash ranged from a high of $147.6 million in Q2 2025 and a low of -$80.7 million during Q3 2025.
  • In the last 3 years, Abeona Therapeutics' Change in Cash had a median value of $1.5 million in 2023 and averaged $6.2 million.
  • Over the last 5 years, Abeona Therapeutics' Change in Cash had its largest YoY gain of 991.78% in 2024, and its largest YoY loss of 1,135.96% in 2024.
  • Quarterly analysis of 5 years shows Abeona Therapeutics' Change in Cash stood at -$5.9 million in 2021, then spiked by 158.78% to $3.5 million in 2022, then spiked by 180.17% to $9.8 million in 2023, then dropped by 21.82% to $7.6 million in 2024, then plummeted by 331.29% to -$80.7 million in 2025.
  • Its Change in Cash was -$80.7 million in Q3 2025, compared to $147.6 million in Q2 2025 and -$7.4 million in Q1 2025.